cannabidiol

Pharma

Jazz must hash new plan for cannabis drug after MS trial failure

Jazz said that its nabiximols oromucosal spray has flunked a phase 3 trial, coming up short in helping multiple sclerosis patients with spasticity.
Kevin Dunleavy Jun 28, 2022 10:35am

RLS bags $10M to trial dry powder inhaled CBD in anxiety

Apr 12, 2022 8:00am

GW plots path to new drug approvals as Epidiolex coasts

Nov 5, 2020 11:14am

GW Pharma takes docs on virtual trip to marijuana greenhouse

Jun 18, 2019 4:42pm

Cannabinoid hopeful FSD taps rival’s veteran executive as CEO

Nov 26, 2018 10:43am

GW Pharma looks to dispel cannabis stigma with Epidiolex launch

Oct 5, 2018 11:24pm